Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on February 1, 2021. The filing reports the entry into a Material Definitive Agreement regarding a new equity financing arrangement.
Key Financial Metrics and Transaction Details
- Transaction Type: At-the-market (ATM) Sales Agreement.
- Counterparty: A.G.P./Alliance Global Partners (Sales Agent).
- Maximum Offering Size: Up to $20,000,000 of common stock.
- Commission Rate: 3.0% of gross proceeds from each sale.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes and Use of Proceeds
The primary material change is the establishment of a mechanism to sell shares up to $20 million. The Company intends to use net proceeds for the following purposes:
- Funding pre-clinical development of the SARS-CoV-2 vaccine, Terra CoV-2.
- Advancing the lantibiotics program.
- General corporate purposes, including research and development and capital expenditures.
- Redemption of all or a portion of outstanding Series C Preferred Stock at its stated value.
- Working capital.
Guidance, Risks, and Contingencies
The Company has no obligation to sell any shares and may suspend offers at any time. The offering may terminate upon the Agent's election due to adverse events, 10 days' advance notice from either party, or the sale of all shares. The filing includes standard forward-looking statement disclaimers regarding market conditions and the ability to satisfy closing conditions.
Key Facts for Investor Verification
- Verify the current trading price of OGEN to assess potential dilution from the $20 million ATM facility.
- Confirm the outstanding balance and redemption terms of the Series C Preferred Stock mentioned as a potential use of proceeds.
- Review the Company's most recent 10-K or 10-Q for actual cash position and burn rate to evaluate the necessity of this financing.
- Monitor future filings for actual sales volumes and proceeds generated under this Sales Agreement.